219 related articles for article (PubMed ID: 9218428)
1. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
2. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
Saenko E; Sarafanov A; Greco N; Shima M; Loster K; Schwinn H; Josic D
J Chromatogr A; 1999 Aug; 852(1):59-71. PubMed ID: 10480230
[TBL] [Abstract][Full Text] [Related]
3. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
4. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
5. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
[TBL] [Abstract][Full Text] [Related]
6. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII.
Saenko EL; Loster K; Josic D; Sarafanov AG
Thromb Res; 1999 Dec; 96(5):343-54. PubMed ID: 10605949
[TBL] [Abstract][Full Text] [Related]
7. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
8. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.
Layet S; Girma JP; Obert B; Peynaud-Debayle E; Bihoreau N; Meyer D
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):129-37. PubMed ID: 1531749
[TBL] [Abstract][Full Text] [Related]
9. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
10. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.
Foster PA; Fulcher CA; Marti T; Titani K; Zimmerman TS
J Biol Chem; 1987 Jun; 262(18):8443-6. PubMed ID: 3110147
[TBL] [Abstract][Full Text] [Related]
11. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
Saenko EL; Scandella D; Yakhyaev AV; Greco NJ
J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404
[TBL] [Abstract][Full Text] [Related]
12. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
14. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
Cao W; Sabatino DE; Altynova E; Lange AM; Casina VC; Camire RM; Zheng XL
J Biol Chem; 2012 Sep; 287(39):32459-66. PubMed ID: 22854959
[TBL] [Abstract][Full Text] [Related]
15. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
16. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.
Lin JC; Ettinger RA; Schuman JT; Zhang AH; Wamiq-Adhami M; Nguyen PC; Nakaya-Fletcher SM; Puranik K; Thompson AR; Pratt KP
PLoS One; 2015; 10(1):e0116577. PubMed ID: 25615825
[TBL] [Abstract][Full Text] [Related]
17. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain.
Jorieux S; Gaucher C; Piétu G; Chérel G; Meyer D; Mazurier C
Br J Haematol; 1994 May; 87(1):113-8. PubMed ID: 7524613
[TBL] [Abstract][Full Text] [Related]
18. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
Thromb Haemost; 1990 Jun; 63(3):403-6. PubMed ID: 2119526
[TBL] [Abstract][Full Text] [Related]
19. Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.
Chiu PL; Bou-Assaf GM; Chhabra ES; Chambers MG; Peters RT; Kulman JD; Walz T
Blood; 2015 Aug; 126(8):935-8. PubMed ID: 26065652
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
